Kevin Hern | Vice President, Investor Relations |
Dave Ricks | Chair and CEO |
Anat Ashkenazi | Chief Financial Officer |
Dr. Dan Skovronsky | Chief Scientific and Medical Officer |
Anne White | President, Lilly Neuroscience |
Ilya Yuffa | President, Lilly International |
Jake Van Naarden | Chief Executive Officer, Loxo Oncology, Lilly and President, Lilly Oncology |
Mike Mason | President, Lilly Diabetes |
Patrik Jonsson | President, Lilly Immunology and Lilly USA |
Sara Smith | Investor Relations |
Kento Ueha | Investor Relations |
Lauren Zierke | Investor Relations |
Louise Chen | Cantor |
Terence Flynn | Morgan Stanley |
Geoff Meacham | Bank of America |
Chris Schott | JPMorgan |
Andrew Baum | Citi |
Seamus Fernandez | Guggenheim |
Alice Nettleton | Wolfe Research |
Umer Raffat | Evercore |
Steve Scala | Cowen |
Vamil Divan | Mizuho |
Kerry Holford | Berenberg |
Evan Seigerman | BMO |
Chris Shibutani | Goldman Sachs |
Robyn Karnauskas | Truist Securities |
Ladies and gentlemen, thank you for standing by. And welcome to the Lilly Q1 2022 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Instructions will be given at that time.